Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
March 10, 2022 16:01 ET
|
Oncternal Therapeutics
Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on...
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
March 07, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer
January 20, 2022 16:05 ET
|
Oncternal Therapeutics
Session will include a discussion of the treatment landscape for Mantle Cell Lymphoma, including potential role of Zilovertamab, Oncternal’s ROR1 antibody ready for Phase 3 in R/R MCL, with recent FDA...
Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma
January 04, 2022 16:01 ET
|
Oncternal Therapeutics
The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus...
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021
December 13, 2021 08:00 ET
|
Oncternal Therapeutics
Updated mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) data from the CIRLL study are encouraging, and comparable to previous results presented at ASCO 2021Objective response rate...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2021 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed/Refractory Ewing Sarcoma at CTOS 2021 Virtual Annual Meeting
November 15, 2021 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference
November 09, 2021 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
November 04, 2021 16:05 ET
|
Oncternal Therapeutics
Progressed the development of zilovertamab (formerly cirmtuzumab) for the treatment of patients with mantle cell lymphoma, including ongoing interactions with the US FDA on potential registration...